ROCKET PHARMACEUTICALS, INC.
For the period ended Jun 30, 2026. Filed Aug 10, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Restricted Stock Units
The following table summarizes the Company’s RSU activity for thesix months ended June 30, 2026:
| Weighted Average | ||
|---|---|---|
| Number of | Grant Date | |
| Shares | Fair Value | |
| Unvested as of December 31, 2025 | 5,000,566 | $6.51 |
| Granted | 4,338,039 | 4.19 |
| Vested(1) | (1,351,771) | 8.22 |
| Forfeited | (691,375) | 6.18 |
| Unvested as of June 30, 2026 | 7,295,459 | $4.84 |
(1) Includes 227,667 vested shares for the six months ended June 30, 2026, that were not distributed until July 2026.
The total grant date fair value of RSUs vested during the six months ended June 30, 2026 and 2025 was$11.1 million and$11.1 million, respectively.
The total distribution date fair value of RSUs distributed during the six months ended June 30, 2026 and 2025 was$4.3 million and$3.9 million, respectively.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.